Literature DB >> 29335652

Kidney cancer: First-in-class HIF2α antagonist safe and effective.

Peter Sidaway.   

Abstract

Entities:  

Year:  2018        PMID： 29335652     DOI： 10.1038/nrclinonc.2018.3

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Authors:  Kevin D Courtney; Jeffrey R Infante; Elaine T Lam; Robert A Figlin; Brian I Rini; James Brugarolas; Naseem J Zojwalla; Ann M Lowe; Keshi Wang; Eli M Wallace; John A Josey; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2017-12-19       Impact factor: 44.544
  1 in total
  1 in total

Review 1.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.